First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors

Summary

This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts BOIN design to identify the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC106.

Timeline

Start

2026-08-18

Primary completion

2028-12-01

Completion

2028-12-01

Drugs

Indications

No indication recorded.